| 词条 | Biotie Therapies | |||||||||||||||||||||||||||||||||||||
| 释义 |
|name = Biotie Therapies Oyj |logo = File:Biotie Therapies logo.png |type = Publicly traded |traded_as = {{OMX|HEX24243|BTH1V}} {{NASDAQ was|BITI}} |foundation = 1998 |location = Turku, Finland |key_people = Timo Veromaa (CEO), Peter Fellner (Chairman of the Board) |industry = Biotechnology |products = |revenue = {{gain}} € 4.8 million (2012)[1]{{rp|p. 11}} |operating_income = {{gain}} (€25.6 million) (2012)[1]{{rp|p. 11}} |num_employees = 38 (end 2012)[1]{{rp|p. 8}} |homepage = Biotie.com }} Biotie Therapies was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki. OverviewBiotie Therapies was formed in the merger of Biotie Therapies Corp. (incorporated in 1998),[2] Oy Contral Pharma Ltd and Carbion Inc in the year 2002. In 2008, Biotie Therapies acquired the German pharmaceutical discovery and development company elbion GmbH in Radebeul. In 2010 Biotie Therapies all preclinical assets were transferred into a new company, biocrea GmbH, in which Biotie become a minority shareholder. In 2011, Biotie acquired a pharmaceutical company Synosia.[3] The company has partnering agreements with H. Lundbeck A/S and UCB.[4][5] In January 2016, Acorda Therapeutics acquired Biotie Therapies for $363 million.[6] Product pipeline
Selincro (nalmefene)The company's most advanced product, Nalmefene, for the treatment of alcoholism. Biotie’s partner H. Lundbeck A/S received European marketing authorization from the European Commission on 28 February 2013. Lundbeck expects to launch Selincro in its first markets in middle of 2013.[7] Studies have shown, that nalmefene has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five units of alcohol. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time.[4][12][13] TozadenantSYN115 also called tozadenant is developed for Parkinson's disease. The product has a potential to be the first new treatment modality for the disease in more than 20 years. The product is an orally administered, potent and selective inhibitor of the adenosine 2a receptor. It is being developed for the treatment of Parkinson's disease, but may also have potential for other CNS disorders.[14] VAP-1Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody - intended for treatment of inflammatory diseases, is currently in Phase I clinical trials with rheumatoid arthritis patients. According to the company, inhibiting VAP-1 reduces inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and psoriasis.[15]NepicastatSYN117 also called nepicastat is a treatment for cocaine dependency and post traumatic stress disorder (PTSD). It is orally administered, potent and selective inhibitor of the enzyme dopamine β-hydroxylase (DBH).[16] RonomilastRonomilast is a PDE4 inhibitor for chronic inflammatory disorders. It is a small molecule phosphodiesterase-4 inhibitor (PDE4). The product is developed for the treatment of chronic obstructive pulmonary disease (COPD). Data from pre-clinical and early clinical trials indicates that the product has a good safety profile. Biotie is in the process of planning a Phase 2 trial in COPD patients and also seeking a partner for late-stage development of ronomilast.[17] References1. ^1 2 {{cite web |url=http://hugin.info/132030/R/1683596/551050.pdf |format=PDF |title=Financial statements 2012 |publisher=Biotie Therapies |accessdate=9 March 2013 }}{{Self-published source|date=March 2018}} 2. ^{{cite news |title=Biotie Therapies on deck for U.S. debut |date=5 June 2015 |work=Seeking Alpha |author=House, Douglas W. |url=http://seekingalpha.com/news/2564956-biotie-therapies-on-deck-for-u-s-debut?ifp=0 }} 3. ^{{Cite press release |url=http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |title=The acquisition of Synosia Therapeutics Holding AG completed |date=February 2, 2011 |archiveurl=https://web.archive.org/web/20110819062317/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |archivedate=August 19, 2011 |deadurl=yes |publisher=Biotie Therapies }}{{Self-published source|date=March 2018}} 4. ^1 Biotie Therapies Oyj Company Description Business Week{{Dead link|date=March 2018}} 5. ^{{Cite news |url=http://www.biotie.com/en/about_us/collaborations |title=Biotie.com, Collaborations |date=February 14, 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20120427210923/http://www.biotie.com/en/about_us/collaborations |archivedate=April 27, 2012 }}{{Self-published source|date=March 2018}} 6. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/acorda-acquires-biotie-therapies-for-363m/81252255/|title=Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN|publisher=}} 7. ^1 {{cite press release |url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |title=Biotie: Selincro (nalmefene) receives European marketing authorization |date=28 February 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130603062733/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |archivedate=June 23, 2013 |publisher=Biotie Therapies }}{{Self-published source|date=March 2018}} 8. ^{{cite press release |url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |title=Stock Exchange Release 27 February 2013 |date=27 February 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130603065527/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |archivedate=June 3, 2013 |publisher=Biotie Therapies }}{{Self-published source|date=March 2018}} 9. ^{{cite press release | url=http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1667335&NewsItemYear=2012 |title=Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder |publisher=Biotie Therapies |date=December 27, 2012 |archivedate=March 4, 2013 |archiveurl=https://web.archive.org/web/20130304011035/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1667335&NewsItemYear=2012 }}{{Self-published source|date=March 2018}} 10. ^[https://archive.is/20130407192253/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1565991&NewsItemYear=2011] Stock Exchange release 23 November 2011 11. ^{{Cite news |url=http://www.biotie.com/en/product_and_development/development_pipeline |title=Biotie.com, Pipeline |date=February 14, 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130215105948/http://www.biotie.com/en/product_and_development/development_pipeline |archivedate=2013-02-15 |df= }} 12. ^Lundbeck announces start of new phase III clinical trials with nalmefene {{webarchive |url=https://web.archive.org/web/20081222040053/http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1277334&NewsItemYear=2008 |date=December 22, 2008 }} STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m 13. ^Balanced CNS and inflammation product pipeline {{webarchive |url=https://web.archive.org/web/20100425231123/http://www.biotie.com/Webroot/1009506/SubPageWide.aspx?id=1010246 |date=April 25, 2010 }} Company website 2008-03-15 14. ^{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |title=Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson’s disease |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111228055904/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |archivedate=2011-12-28 |df= }} 15. ^INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2008{{dead link|date=November 2016 |bot=InternetArchiveBot |fix-attempted=yes }} 16. ^{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |title=Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD) |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111113105320/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |archivedate=2011-11-13 |df= }} 17. ^{{Cite news |url=http://www.biotie.com/en/product_and_development/inflammation/ronomilast |title=Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111113101956/http://www.biotie.com/en/product_and_development/inflammation/ronomilast |archivedate=2011-11-13 |df= }} External links
8 : Companies listed on the Helsinki Stock Exchange|Pharmaceutical companies of Finland|Pharmaceutical companies established in 1998|Companies formerly listed on NASDAQ|Biotechnology companies of Finland|Parkinson's disease|Biotechnology companies established in 1998|1998 establishments in Finland |
|||||||||||||||||||||||||||||||||||||
| 随便看 |
|
|||||||||||||||||||||||||||||||||||||
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。